This Article Full Text Full Text (PDF) All Versions of this Article: 46/1/151    most recent 01.HYP.0000171165.80268.bev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amar, J. Articles by Chamontin, B. Search for Related Content PubMed PubMed Citation Articles by Amar, J. Articles by Chamontin, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATENOLOL Medline Plus Health Information High Blood Pressure Related Collections Risk Factors Clinical Studies

(Hypertension. 2005;46:151.)
© 2005 American Heart Association, Inc.

Original Articles

C-Reactive Protein Elevation Predicts Pulse Pressure Reduction in Hypertensive Subjects

Jacques Amar; Jean-Bernard Ruidavets; Jean-Claude Peyrieux; Jean-Michel Mallion; Jean Ferrières; Michel E. Safar; Bernard Chamontin

From the Department of Internal Medicine and Hypertension (J.A., B.C.), CHU Purpan; INSERM U558 (J.A., B.C., J.-B.R., J.F.), Department of Epidemiology, Faculty of Medicine, Toulouse; Statmed (J.-C.P.), Lyon; Department of Cardiology and Hypertension (J.-M.M.), CHU Grenoble; and Diagnostic Center (M.E.S.), Hôtel Dieu, Paris, France.

Correspondence to Prof Jacques Amar, Service de Médecine Interne et d’Hypertension Artérielle, CHU Purpan, TSA 40031, 31059 Toulouse Cedex 9, France. E-mail amar.j{at}chu-toulouse.fr

Cross-sectional studies have shown a positive association between increased pulse pressure (PP) and an increased likelihood of a C-reactive protein (CRP) level >3 mg/L. In a retrospective subgroup analysis of the hypertensive subjects of the multicenter double-blind study, REASON (PREterax in Regression of Arterial Stiffness in a ContrOlled Double-BliNd), in which fixed first-line antihypertensive combination therapy with an angiotensin converting enzyme (ACE) inhibitor, perindopril (2 mg), and a diuretic, indapamide (0.625 mg), proved significantly more effective than atenolol in normalizing PP, we sought to determine whether perindopril plus indapamide was also more effective than atenolol in lowering CRP levels and, if so, whether this effect correlated with a preferential reduction in PP. At the final visit (12 months) in the 269 patients studied, the decrease in PP was greater, and the proportion of patients with CRP >3 mg/L lower (17.9% versus 28. 9%, P=0.03; adjusted odds ratio, 1.02 to 4.08, P=0.01), in the perindopril plus indapamide group than in the atenolol group. After adjustment for confounders, patients with a baseline CRP >3 mg/L displaying the greatest decrease in PP were more likely (P=0.04) to have a CRP 3 mg/L at 12 months. No such relationship was found with systolic or diastolic blood pressure. Perindopril–indapamide combination therapy is more effective than ß-blockade in lowering elevated CRP in hypertensive subjects. This effect is significantly associated with a more effective PP reduction in patients with baseline CRP >3 mg/L.

Key Words: clinical science • antihypertensive drugs • clinical trials

This article has been cited by other articles:

				G. Cai, S. A. Cole, N. F. Butte, V. S. Voruganti, and A. G. Comuzzie A Quantitative Trait Locus on Chromosome 13q Affects Fasting Glucose Levels in Hispanic Children J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4893 - 4896. [Abstract] [Full Text] [PDF]

				M. E. Safar Mechanism(s) of Systolic Blood Pressure Reduction and Drug Therapy in Hypertension Hypertension, July 1, 2007; 50(1): 167 - 171. [Full Text] [PDF]

				S. Laurent and P. Boutouyrie Recent Advances in Arterial Stiffness and Wave Reflection in Human Hypertension Hypertension, June 1, 2007; 49(6): 1202 - 1206. [Full Text] [PDF]

				M. E. Safar and A. Fournier Letter by Safar and Fournier Regarding Article, "Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study" Circulation, October 10, 2006; 114(15): e539 - e539. [Full Text] [PDF]